Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

CASI Approved to Start Fourth China Phase II Trial of Cancer Drug

publication date: May 12, 2016
CASI Pharma, a US-China biopharma, received CFDA approval to extend the US Phase II trial of its lead molecule (ENMD-2076) in fibrolamellar carcinoma into China. CASI is already testing ENMD-2076 in three additional US-China Phase II trials for other indications. ENMD-2076 is an oral Aurora A/angiogenic kinase inhibitor that slows cell division and inhibits formation of new blood vessels. Headquartered in Maryland with a lab in Beijing, CASI in-licenses products for the China market, but the company is developing ENMD-2076 globally. More details....

Stock Symbol: (NSDQ: CASI)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital